Oncologic outcomes after adjuvant radiotherapy for stage II endometrial carcinoma: A Korean Radiation Oncology Group study (KROG 14Y10)

Jinhong Jung, Young Seok Kim, Ji Hyeon Joo, Won Park, Jong Hoon Lee, Jin Hee Kim, Won Sup Yoon, Seok Ho Lee, Keun Yong Eom, Yongbae Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: The aim of this study was to investigate the survival, patterns of failure, and prognostic factors in patients with stage II endometrial carcinoma treated with adjuvant radiotherapy. Methods: We reviewed the medical records of patients who underwent total hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymph node dissection followed by adjuvant radiotherapy in 10 participating hospitals of the Korean Radiation Oncology Group. Most patients received adjuvant external beam radiation therapy, with a median dose of 50.4 Gy; approximately 50% of these patients received an additional brachytherapy boost, with a median dose of 18 Gy. Adjuvant chemotherapy was administered to 19 patients. Results: A total of 122 patients were examined. Over a median follow-up period of 62.7 months (range, 1.9Y158.8 months), the 5-year overall survival (OS) and disease-free survival rates were found to be 91.1% and 85.1%, respectively. Recurrence was observed in 14 patients (11.5%), including 3 with local recurrence and 11 with distant metastases as the first site of recurrence. Univariate analysis indicated that lymphovascular invasion was related to an unfavorable OS. An age of 60 years or above, histologic grade 3, and lymphovascular invasion were identified as risk factors for OS. Because therewere several risk factors related to OS, we assigned patients to a high-risk group (defined as cases with Q1 risk factors) and a low-risk group. The 5-year OS rate of the high-risk group was significantly inferior to that of the low-risk group (82.9% vs 100%, P = 0.003). Conclusions: The high-risk group had a significantly poorer survival rate than the low-risk group, and distant metastasis was the main pattern of recurrence, thus indicating that further adjuvant chemotherapy should be considered in high-risk patients.

Original languageEnglish
Pages (from-to)1387-1392
Number of pages6
JournalInternational Journal of Gynecological Cancer
Volume27
Issue number7
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Adjuvant Radiotherapy
Radiation Oncology
Endometrial Neoplasms
Survival
Recurrence
Survival Rate
Adjuvant Chemotherapy
Neoplasm Metastasis
Brachytherapy
Ovariectomy
Lymph Node Excision
Hysterectomy
Disease-Free Survival
Medical Records
Radiotherapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynaecology

Cite this

Jung, Jinhong ; Kim, Young Seok ; Joo, Ji Hyeon ; Park, Won ; Lee, Jong Hoon ; Kim, Jin Hee ; Yoon, Won Sup ; Lee, Seok Ho ; Eom, Keun Yong ; Kim, Yongbae. / Oncologic outcomes after adjuvant radiotherapy for stage II endometrial carcinoma : A Korean Radiation Oncology Group study (KROG 14Y10). In: International Journal of Gynecological Cancer. 2017 ; Vol. 27, No. 7. pp. 1387-1392.
@article{040047ef866d4f929585a2d8f3c282a8,
title = "Oncologic outcomes after adjuvant radiotherapy for stage II endometrial carcinoma: A Korean Radiation Oncology Group study (KROG 14Y10)",
abstract = "Objective: The aim of this study was to investigate the survival, patterns of failure, and prognostic factors in patients with stage II endometrial carcinoma treated with adjuvant radiotherapy. Methods: We reviewed the medical records of patients who underwent total hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymph node dissection followed by adjuvant radiotherapy in 10 participating hospitals of the Korean Radiation Oncology Group. Most patients received adjuvant external beam radiation therapy, with a median dose of 50.4 Gy; approximately 50{\%} of these patients received an additional brachytherapy boost, with a median dose of 18 Gy. Adjuvant chemotherapy was administered to 19 patients. Results: A total of 122 patients were examined. Over a median follow-up period of 62.7 months (range, 1.9Y158.8 months), the 5-year overall survival (OS) and disease-free survival rates were found to be 91.1{\%} and 85.1{\%}, respectively. Recurrence was observed in 14 patients (11.5{\%}), including 3 with local recurrence and 11 with distant metastases as the first site of recurrence. Univariate analysis indicated that lymphovascular invasion was related to an unfavorable OS. An age of 60 years or above, histologic grade 3, and lymphovascular invasion were identified as risk factors for OS. Because therewere several risk factors related to OS, we assigned patients to a high-risk group (defined as cases with Q1 risk factors) and a low-risk group. The 5-year OS rate of the high-risk group was significantly inferior to that of the low-risk group (82.9{\%} vs 100{\%}, P = 0.003). Conclusions: The high-risk group had a significantly poorer survival rate than the low-risk group, and distant metastasis was the main pattern of recurrence, thus indicating that further adjuvant chemotherapy should be considered in high-risk patients.",
author = "Jinhong Jung and Kim, {Young Seok} and Joo, {Ji Hyeon} and Won Park and Lee, {Jong Hoon} and Kim, {Jin Hee} and Yoon, {Won Sup} and Lee, {Seok Ho} and Eom, {Keun Yong} and Yongbae Kim",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/IGC.0000000000001030",
language = "English",
volume = "27",
pages = "1387--1392",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

Oncologic outcomes after adjuvant radiotherapy for stage II endometrial carcinoma : A Korean Radiation Oncology Group study (KROG 14Y10). / Jung, Jinhong; Kim, Young Seok; Joo, Ji Hyeon; Park, Won; Lee, Jong Hoon; Kim, Jin Hee; Yoon, Won Sup; Lee, Seok Ho; Eom, Keun Yong; Kim, Yongbae.

In: International Journal of Gynecological Cancer, Vol. 27, No. 7, 01.01.2017, p. 1387-1392.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Oncologic outcomes after adjuvant radiotherapy for stage II endometrial carcinoma

T2 - A Korean Radiation Oncology Group study (KROG 14Y10)

AU - Jung, Jinhong

AU - Kim, Young Seok

AU - Joo, Ji Hyeon

AU - Park, Won

AU - Lee, Jong Hoon

AU - Kim, Jin Hee

AU - Yoon, Won Sup

AU - Lee, Seok Ho

AU - Eom, Keun Yong

AU - Kim, Yongbae

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objective: The aim of this study was to investigate the survival, patterns of failure, and prognostic factors in patients with stage II endometrial carcinoma treated with adjuvant radiotherapy. Methods: We reviewed the medical records of patients who underwent total hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymph node dissection followed by adjuvant radiotherapy in 10 participating hospitals of the Korean Radiation Oncology Group. Most patients received adjuvant external beam radiation therapy, with a median dose of 50.4 Gy; approximately 50% of these patients received an additional brachytherapy boost, with a median dose of 18 Gy. Adjuvant chemotherapy was administered to 19 patients. Results: A total of 122 patients were examined. Over a median follow-up period of 62.7 months (range, 1.9Y158.8 months), the 5-year overall survival (OS) and disease-free survival rates were found to be 91.1% and 85.1%, respectively. Recurrence was observed in 14 patients (11.5%), including 3 with local recurrence and 11 with distant metastases as the first site of recurrence. Univariate analysis indicated that lymphovascular invasion was related to an unfavorable OS. An age of 60 years or above, histologic grade 3, and lymphovascular invasion were identified as risk factors for OS. Because therewere several risk factors related to OS, we assigned patients to a high-risk group (defined as cases with Q1 risk factors) and a low-risk group. The 5-year OS rate of the high-risk group was significantly inferior to that of the low-risk group (82.9% vs 100%, P = 0.003). Conclusions: The high-risk group had a significantly poorer survival rate than the low-risk group, and distant metastasis was the main pattern of recurrence, thus indicating that further adjuvant chemotherapy should be considered in high-risk patients.

AB - Objective: The aim of this study was to investigate the survival, patterns of failure, and prognostic factors in patients with stage II endometrial carcinoma treated with adjuvant radiotherapy. Methods: We reviewed the medical records of patients who underwent total hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymph node dissection followed by adjuvant radiotherapy in 10 participating hospitals of the Korean Radiation Oncology Group. Most patients received adjuvant external beam radiation therapy, with a median dose of 50.4 Gy; approximately 50% of these patients received an additional brachytherapy boost, with a median dose of 18 Gy. Adjuvant chemotherapy was administered to 19 patients. Results: A total of 122 patients were examined. Over a median follow-up period of 62.7 months (range, 1.9Y158.8 months), the 5-year overall survival (OS) and disease-free survival rates were found to be 91.1% and 85.1%, respectively. Recurrence was observed in 14 patients (11.5%), including 3 with local recurrence and 11 with distant metastases as the first site of recurrence. Univariate analysis indicated that lymphovascular invasion was related to an unfavorable OS. An age of 60 years or above, histologic grade 3, and lymphovascular invasion were identified as risk factors for OS. Because therewere several risk factors related to OS, we assigned patients to a high-risk group (defined as cases with Q1 risk factors) and a low-risk group. The 5-year OS rate of the high-risk group was significantly inferior to that of the low-risk group (82.9% vs 100%, P = 0.003). Conclusions: The high-risk group had a significantly poorer survival rate than the low-risk group, and distant metastasis was the main pattern of recurrence, thus indicating that further adjuvant chemotherapy should be considered in high-risk patients.

UR - http://www.scopus.com/inward/record.url?scp=85041648804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041648804&partnerID=8YFLogxK

U2 - 10.1097/IGC.0000000000001030

DO - 10.1097/IGC.0000000000001030

M3 - Article

C2 - 28604455

AN - SCOPUS:85041648804

VL - 27

SP - 1387

EP - 1392

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 7

ER -